NCT00459420View on ClinicalTrials.gov

Caffeine for Excessive Daytime Somnolence in Parkinson's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Parkinson's DiseaseExcessive Daytime Somnolence
Interventions
DRUG

Caffeine 100-200 mg BID

Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo

DRUG

placebo

placebo

Trial Locations (2)

Unknown

Toronto Western Hospital, Toronto

H3G 1A4

Montreal General Hospital, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

University of Toronto

OTHER

lead

Ron Postuma

OTHER

NCT00459420 - Caffeine for Excessive Daytime Somnolence in Parkinson's Disease | Biotech Hunter | Biotech Hunter